Legal Representation
Attorney
Aaron D. Hendelman
USPTO Deadlines
Next Deadline
832 days remaining
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2017-11-07)
Due Date
November 07, 2027
Grace Period Ends
May 07, 2028
Application History
50 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
May 1, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
May 1, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
May 1, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
Jan 30, 2025 | NAS8 | E | NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED | Loading... |
Jan 30, 2025 | 8.PR | O | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED | Loading... |
Jan 30, 2025 | PRAN | O | POST REGISTRATION ACTION MAILED NO RESPONSE REQUIRED | Loading... |
Jan 30, 2025 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... |
Oct 28, 2024 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
Oct 28, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
Oct 28, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
Oct 28, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
Oct 28, 2024 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
Oct 28, 2024 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | Loading... |
May 7, 2024 | ES8R | I | TEAS SECTION 8 RECEIVED | Loading... |
Nov 8, 2023 | ASCK | I | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | Loading... |
Nov 7, 2022 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | Loading... |
May 10, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
May 10, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
May 10, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
Aug 4, 2021 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
May 7, 2018 | EROP | I | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | Loading... |
May 7, 2018 | COC. | O | CORRECTION UNDER SECTION 7 - PROCESSED | Loading... |
Dec 27, 2017 | PRAM | O | POST REGISTRATION ACTION MAILED - SEC. 7 | Loading... |
Dec 27, 2017 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... |
Nov 27, 2017 | FAXX | I | FAX RECEIVED | Loading... |
Nov 20, 2017 | ES7R | I | TEAS SECTION 7 REQUEST RECEIVED | Loading... |
Nov 7, 2017 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
Sep 30, 2017 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
Sep 29, 2017 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
Sep 13, 2017 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
Sep 13, 2017 | DPCC | D | DIVISIONAL PROCESSING COMPLETE | Loading... |
Sep 11, 2017 | IUAF | S | USE AMENDMENT FILED | Loading... |
Sep 11, 2017 | DRRR | I | DIVISIONAL REQUEST RECEIVED | Loading... |
Sep 11, 2017 | ERTD | I | TEAS REQUEST TO DIVIDE RECEIVED | Loading... |
Sep 11, 2017 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
Aug 30, 2017 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
Mar 17, 2017 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Mar 15, 2017 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
Mar 15, 2017 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
Mar 15, 2017 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Nov 30, 2016 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Nov 29, 2016 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
Nov 28, 2016 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
Oct 20, 2016 | NREV | E | NOTICE OF REVIVAL - E-MAILED | Loading... |
Oct 20, 2016 | PROA | I | TEAS PETITION TO REVIVE RECEIVED | Loading... |
Oct 20, 2016 | PETG | O | PETITION TO REVIVE-GRANTED | Loading... |
Oct 20, 2016 | TPEX | I | SOU EXTENSION RECEIVED WITH TEAS PETITION | Loading... |
Oct 20, 2016 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
Oct 17, 2016 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
Oct 17, 2016 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
Detailed Classifications
Class 001
[ Kits containing chemical and biochemical assays and reagents for scientific research use; nucleic acid and protein isolation kits comprised primarily of assays and reagents for use in epigenetic research and analysis; none of the aforementioned involve the use or study of semaphorins ]
First Use Anywhere:
May 1, 2017
First Use in Commerce:
May 1, 2017
Class 005
[ Pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases, namely, cancer and Mendelian disorders; test kits consisting of medical diagnostic reagents and assays for testing in the field of the prevention and treatment of disorders and diseases; none of the aforementioned involve the use or study of semaphorins ]
First Use Anywhere:
May 1, 2017
First Use in Commerce:
May 1, 2017
Class 035
[ Business consulting and business information services regarding precision health diagnosis and personalized treatment; business consulting and business information services regarding the analysis and packaging of health data; providing business information, namely, commercial corporate and statistical information provided on-line from a computer database or the Internet; statistical analysis and reporting services for business purposes; business consulting and business information services regarding the identification of drug targets; business consulting and business information services regarding bioinformatic analysis; population health management ]
First Use Anywhere:
May 1, 2017
First Use in Commerce:
May 1, 2017
Class 042
[ Medical and scientific research in the field of biologic testing and interpretation, diagnosis, treatment, and health maintenance; bioinformatics interpretation of health data; medical and scientific research in the field of ancestry analysis for scientific research purposes; compiling data for research purposes in the field of medical science and medical consultancy for use in connection with diagnostic testing; analysis and screening of nucleic acids for scientific research purposes; genome mapping for scientific purposes; ] providing information in the field of disease classification for use in connection with diagnostic testing [; development of scientific research and technology for purposes of disease diagnosis, preventative health care, health monitoring, and personalized treatment; providing a website featuring non-downloadable software for patient access to health care services and health information; providing a website featuring non-downloadable software for patient access to diagnosis, treatment, and health maintenance information; providing a website featuring non-downloadable software for accessing, viewing, interacting with and downloading personal health records, diagnoses, treatment plans, and health monitoring information; scientific and medical research, namely, identifying drug targets; scientific research relating to population health management; none of the aforementioned involve the use or study of semaphorins ]
First Use Anywhere:
May 1, 2017
First Use in Commerce:
May 1, 2017
Class 044
Diagnostic services in the field of medicine; medical testing for diagnosis of diseases and treatment purposes [; bioinformatics analysis for medical diagnostic and personalized treatment purposes; biochemical testing for ancestry analysis and personalized diagnostics and treatments; nucleic acid analysis and screening for medical diagnostic and treatment purposes; DNA analysis and screening for medical diagnostic and treatment purposes; consulting services in the field of biological sequence and bioinformatic processing for medical diagnosis and treatment purposes; health care services, namely, leveraging health monitoring and data science to provide optimal health and disease prevention to patients; creating personalized preventative health-care programs and disease management programs; providing an online resource center featuring personalized health information based on health information and diagnostics; medical testing, namely, identifying drug targets for diagnostic or treatment purposes; none of the aforementioned involve the use or study of semaphorins ]
First Use Anywhere:
May 1, 2017
First Use in Commerce:
May 1, 2017
Additional Information
Other
In the statement, Column 1, line 1, "New York" should be deleted, and Delaware should be inserted.
Pseudo Mark
SEMA FOUR
Classification
International Classes
001
005
035
042
044